Effectiveness of nirsevimab in infants and young children with bronchiolitis: a systematic review and meta-analysis
Translational Pediatrics · 2026-11 · 15 (11) · 469-469
DOI: 10.21037/tp-2026-0774 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Translational Pediatrics, 2026-11. Verfasst von Yingying Sun und 3 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Acute bronchiolitis ranks among the most common lower respiratory tract infections in infants and young children, with respiratory syncytial virus (RSV) as its primary etiology. Its substantial global incidence and high rate of severe hospitalizations impose a significant healthcare and family burden. Palivizumab, a previously available prophylactic monoclonal antibody, is limited by its narrow indication and requirement for repeated dosing, restricting its clinical utility. Nirsevimab, a novel long-acting monoclonal antibody targeting RSV, offers distinct advantages, including an extended half-life, season-long protection, and single-dose administration. However, its protective efficacy against acute bronchiolitis in infants and young children requires systematic evaluation. This study thus sought to synthesize and evaluate the efficacy of nirsevimab in preventing acute bronchiolitis in infants.
Methods
Comparative studies on nirsevimab use in infants and young children published up to September 2025 were retrieved from PubMed, Embase, Web of Science, and the Cochrane Library via EndNote. The National Institutes of Health (NIH) assessment tools were applied to evaluate the risk of bias, with all meta-analytic procedures implemented using R software (version 4.5.1). Outcomes included nirsevimab immunization rate, RSV detection rate, and duration of hospitalization. Nirsevimab immunization rate was expressed as proportions with 95% confidence interval (CI). For between-group comparisons, risk ratio (RR) with 95% CI were used for dichotomous outcomes, and mean difference (MD) with 95% CI: was used for continuous outcomes.
Results
This analysis included 12 studies involving 6,939 pediatric patients. Nirsevimab immunization rates was 0.39 (95% CI: 0.26, 0.53). Compared with the control group, nirsevimab significantly reduced RSV detection rates (RR =0.54, 95% CI: 0.43, 0.69). Conversely, the duration of hospitalization did not differ significantly between the two groups (MD =0.03, 95% CI: −0.78, 0.85).
Conclusions
Nirsevimab significantly reduces the risk of RSV infection and associated acute bronchiolitis in infants and young children, demonstrating robust protective efficacy. It also contributes to reduced patient morbidity and alleviates the associated socioeconomic burden on families. These findings provide important evidence-based support for RSV preventive strategies in pediatric populations, with substantial potential for clinical translation and public health application.
Zitieren
APA
Sun, Y., Zhou, M., Liu, L., & Sun, L. (2026). Effectiveness of nirsevimab in infants and young children with bronchiolitis: a systematic review and meta-analysis. Translational Pediatrics, 15(11), 469-469. https://doi.org/10.21037/tp-2026-0774
Vancouver
Sun Y, Zhou M, Liu L, Sun L. Effectiveness of nirsevimab in infants and young children with bronchiolitis: a systematic review and meta-analysis. Translational Pediatrics. 2026;15(11):469-469. doi:10.21037/tp-2026-0774
BibTeX
@article{Sun2026,
author = {Sun, Yingying and Zhou, Mengxiao and Liu, Liang and Sun, Liping},
title = {Effectiveness of nirsevimab in infants and young children with bronchiolitis: a systematic review and meta-analysis},
journal = {Translational Pediatrics},
year = {2026},
volume = {15},
number = {11},
pages = {469--469},
doi = {10.21037/tp-2026-0774}
}
EUVIMED